REYVOW Drug Patent Profile
✉ Email this page to a colleague
When do Reyvow patents expire, and what generic alternatives are available?
Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eighteen patent family members in forty-four countries.
The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
DrugPatentWatch® Generic Entry Outlook for Reyvow
Reyvow was eligible for patent challenges on January 31, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 5, 2037. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REYVOW?
- What are the global sales for REYVOW?
- What is Average Wholesale Price for REYVOW?
Summary for REYVOW
| International Patents: | 118 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Patent Applications: | 57 |
| Drug Prices: | Drug price information for REYVOW |
| What excipients (inactive ingredients) are in REYVOW? | REYVOW excipients list |
| DailyMed Link: | REYVOW at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REYVOW
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for REYVOW
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| REYVOW | Tablets | lasmiditan succinate | 50 mg and 100 mg | 211280 | 1 | 2024-01-31 |
US Patents and Regulatory Information for REYVOW
REYVOW is protected by three US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of REYVOW is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting REYVOW
Compositions and methods related to pyridinoylpiperidine 5-HT.sub.1F agonists
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyridinoylpiperidines as 5-HT.sub.1F agonists
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE
FDA Regulatory Exclusivity protecting REYVOW
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for REYVOW
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for REYVOW
When does loss-of-exclusivity occur for REYVOW?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 17373784
Patent: Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2019010934
Patent: composições e métodos relacionados a agonistas de piridinoilpiperidina 5-ht1f
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 43772
Patent: HYDRATES DE 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYLE)-PYRIDIN-2-YL]-BENZAMIDE D'HEMISUCCINATE ET UTILISATIONS CONNEXES EN TANT QU'AGONISTE DE 5-HT1F (HYDRATES OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND USES THEREOF AS A 5-HT1F AGONIST)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 19001426
Patent: Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
Estimated Expiration: ⤷ Sign Up
China
Patent: 0291079
Patent: 与吡啶酰基哌啶5-HT激动剂相关的组合物和方法 (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 5385893
Patent: 与吡啶酰基哌啶5-HT1F激动剂相关的组合物和方法 (Compositions and methods related to picolinylpiperidine 5-HT1F agonists)
Estimated Expiration: ⤷ Sign Up
Patent: 5385894
Patent: 与吡啶酰基哌啶5-HT1F激动剂相关的组合物和方法 (Compositions and methods related to picolinylpiperidine 5-HT1F agonists)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 19005290
Patent: Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 190251
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT 1F (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0211557
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 24540
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 51617
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 019000139
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 19040190
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1991112
Patent: КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ С ПИРИДИНОИЛПИПЕРИДИНОВЫМИ АГОНИСТАМИ 5-HT1F
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 51617
Patent: COMPOSITIONS ET PROCÉDÉS SE RAPPORTANT À DES AGONISTES DE PYRIDINOYLPIPÉRIDINE 5-HT1F (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 56820
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 6598
Patent: תכשירים ושיטות הקשורים לאגוניסטים של פירידינוילפיפרידין 5-ht1f (Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 20500936
Patent: ピリジノイルピペリジン５−ＨＴ１Ｆアゴニストに関する組成物および方法
Estimated Expiration: ⤷ Sign Up
Patent: 22000451
Patent: ピリジノイルピペリジン５−ＨＴ１Ｆアゴニストに関する組成物および方法 (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 23123678
Patent: ピリジノイルピペリジン５－ＨＴ１Ｆアゴニストに関する組成物および方法 (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 0190129
Patent: تركيبات وطرق تتعلق بمواد مساعدة لـ 5-HT1F من بيريدينويل بيبريدين (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 51617
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 6855
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 19006520
Patent: COMPOSICIONES Y METODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F. (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS.)
Estimated Expiration: ⤷ Sign Up
Patent: 21014139
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F. (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS.)
Estimated Expiration: ⤷ Sign Up
Moldova, Republic of
Patent: 51617
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 920
Patent: COMPOSITIONS ET PROCÉDÉS SE RAPPORTANT À DES AGONISTES DE PYRIDINOYLPIPÉRIDINE 5-HT1F
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 2906
Patent: Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 191134
Patent: COMPOSICIONES Y METODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 019501252
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HTIF AGONISTS
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 51617
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 51617
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 415
Patent: FARMACEUTSKI OBLICI I METODE KOJI SE ODNOSE NA PIRIDINOILPIPERIDIN 5-HT1F AGONISTE (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 51617
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1903449
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 190075130
Patent: 피리디노일피페리딘 5-HT1F 작용제에 관한 조성물 및 방법
Estimated Expiration: ⤷ Sign Up
Patent: 210102497
Patent: 피리디노일피페리딘 5-HT1F 작용제에 관한 조성물 및 방법 (5-HT1F COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 230008257
Patent: 피리디노일피페리딘 5-HT1F 작용제에 관한 조성물 및 방법 (5-HT1F COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 89476
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 71290
Estimated Expiration: ⤷ Sign Up
Patent: 1833097
Patent: Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 19000174
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 4433
Patent: ПІРИДИНОЇЛПІПЕРИДИН, ЙОГО ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ МІГРЕНІ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering REYVOW around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Chile | 2023003040 | Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida | ⤷ Sign Up |
| Croatia | P20040883 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ⤷ Sign Up |
| Norway | 330394 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
